To improve both the homogeneity and the stability of ADCs, we have developed site-specific
drug-conjugating reagents that covalently rebridge reduced disulfide bonds. The new …

The conjugation of monomethyl auristatin E (MMAE) to trastuzumab using a reduction bis-alkylation
approach that is capable of rebridging reduced (native) antibody interchain disulfide …

Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have
undergone substantial development over the past decade and are now achieving clinical …

We herein describe the cell-specific release of alcohol-containing payloads via a sulfatase-sensitive
linker in antibody-drug conjugates (ADCs). The linker shows efficient sulfatase-…

Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer
therapeutics with ten clinical approvals to date. As the field matures, much attention has focused …

Introduction Secretory leucocyte protease inhibitor and elafin are members of the whey acidic
protein (WAP), or WAP four disulfide-core (WFDC), family of proteins and have multiple …

An analogue of the bisphosphonate drug Ibandronate was prepared and coupled via a
cleavable ester function to a bromoacetyl linker with specific reactivity for thiol groups. This …

Monoclonal antibodies and derivative formats such as Fab′ fragments are used in a broad
range of therapeutic, diagnostic and research applications. New systems and …

Secretory leukocyte protease inhibitor (SLPI) is an important respiratory tract protease
inhibitor also possessing antimicrobial and anti-inflammatory properties. SLPI has shown …

Prader-Willi syndrome (PWS) is the leading genetic cause of obesity. After initial severe
hypotonia, PWS children become hyperphagic and morbidly obese, if intake is not restricted. …